Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Quidel Corporation discovers, develops, manufactures, and markets diagnostic healthcare products and solutions. The Company offers diagnostic solutions which help in the detection and diagnosis of critical diseases and other medical conditions, including infectious, women health, gastrointestinal, autoimmune, and bone health and thyroid diseases.
Website: quidel.com



Growth: Bad revenue growth rate -5.1%, there is slowdown compared to average historical growth rates 61.0%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +41.7%

Profitability: LTM EBITDA margin is positive, +8.0%. On average the margin is decreasing unsteadily. Gross margin is high, +49.5%. In the last quarter the company beat the estimated EPS, +20.8%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$0.15 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 4.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 11.9% higher than minimum and 75.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.0x by EV / Sales multiple , the company can be >100% undervalued

Insiders: For the last 3 months insiders bought company shares on $0.1 mln (0.003% of cap.)

Key Financials (Download financials)

Ticker: QDEL
Share price, USD:  (-2.7%)42.82
year average price 67.22  


year start price 87.44 2023-05-20

max close price 89.25 2023-05-22

min close price 38.26 2024-04-18

current price 42.82 2024-05-18
Common stocks: 66 300 000

Dividend Yield:  0.0%
FCF Yield LTM: 4.6%
EV / LTM EBITDA: 21.2x
EV / EBITDA annualized: 33.0x
Last revenue growth (y/y):  -5.1%
Last growth of EBITDA (y/y):  -42.9%
Historical revenue growth:  61.0%
Historical growth of EBITDA:  20.0%
EV / Sales: 1.7x
Margin (EBITDA LTM / Revenue): 8.0%
Fundamental value created in LTM:
Market Cap ($m): 2 839
Net Debt ($m): 2 438
EV (Enterprise Value): 5 277
Price to Book: 0.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-05-17prnewswire.com

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - QDEL

2024-05-17accesswire.com

Levi & Korsinsky Reminds QuidelOrtho Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 11, 2024 - QDEL

2024-05-17accesswire.com

Levi & Korsinsky Notifies Shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL) of a Class Action Lawsuit and an Upcoming Deadline

2024-05-17prnewswire.com

QuidelOrtho Corporation f/k/a Quidel Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before June 11, 2024 to Discuss Your Rights - QDEL

2024-05-16accesswire.com

QDEL LAWSUIT ALERT: Levi & Korsinsky Notifies QuidelOrtho Corporation f/k/a Quidel Corporation Investors of a Class Action Lawsuit and Upcoming Deadline

2024-05-16accesswire.com

Lost Money on QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

2024-05-16accesswire.com

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) Shareholders

2024-05-16accesswire.com

QuidelOrtho Corporation f/k/a Quidel Corporation Class Action: Levi & Korsinsky Reminds QuidelOrtho Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 11, 2024 - QDEL

2024-05-09Zacks Investment Research

QuidelOrtho (QDEL) Q1 Earnings Beat Estimates, Margins Fall

2024-05-08Zacks Investment Research

Here's What Key Metrics Tell Us About QuidelOrtho (QDEL) Q1 Earnings
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-10-01 2023-07-02 2023-04-02 2023-01-01 2022-10-02
symbol QDEL QDEL QDEL QDEL QDEL QDEL QDEL
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-09 2024-02-29 2023-11-02 2023-08-09 2023-05-04 2023-02-23 2022-11-04
acceptedDate 2024-05-08 18:04:23 2024-02-29 15:29:59 2023-11-01 18:04:39 2023-08-08 18:11:48 2023-05-04 16:09:15 2023-02-23 17:16:50 2022-11-03 20:40:53
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 710M 743M 744M 665M 846M 867M 784M
costOfRevenue 432M 423M 376M 369M 398M 418M 376M
grossProfit 278M 320M 368M 296M 449M 449M 408M
grossProfitRatio 0.391 0.431 0.495 0.446 0.530 0.518 0.520
researchAndDevelopmentExpenses 59M 59M 62M 63M 62M 64M 66M
generalAndAdministrativeExpenses 0 173M 0 0 0 25M 0
sellingAndMarketingExpenses 0 15M 0 0 0 -65M 0
sellingGeneralAndAdministrativeExpenses 205M 188M 194M 179M 202M 214M 204M
otherExpenses -8M -50M -4M -1 000 000 55M 58M 55M
operatingExpenses 272M 247M 315M 299M 319M 336M 324M
costAndExpenses 704M 670M 691M 668M 717M 754M 701M
interestIncome 900 000 -4M 1M 2M 1 000 000 300 000 300 000
interestExpense 46M 37M 38M 37M 37M 35M 30M
depreciationAndAmortization 115M -180M 51M 51M 78M 70M 51M
ebitda 121M 40M 100M 48M 177M 156M 138M
ebitdaratio 0.170 0.054 0.135 0.072 0.209 0.180 0.176
operatingIncome 6M 40M 26M -27M 100M 87M 87M
operatingIncomeRatio 0.008 0.054 0.035 -0.040 0.118 0.100 0.112
totalOtherIncomeExpensesNet -1 805M -49M -31M -25M -40M -45M -56M
incomeBeforeTax -1 799M -9M -16M -64M 60M 41M 31M
incomeBeforeTaxRatio -2.535 -0.012 -0.021 -0.097 0.071 0.047 0.040
incomeTaxExpense -93M -16M -3M -11M 11M 11M 12M
netIncome -1 706M 7M -13M -53M 49M 30M 19M
netIncomeRatio -2.404 0.009 -0.017 -0.080 0.058 0.035 0.024
eps -25.500 0.100 -0.190 -0.800 0.730 0.460 0.290
epsdiluted -25.500 0.100 -0.190 -0.800 0.730 0.450 0.280
weightedAverageShsOut 67M 67M 67M 67M 67M 66M 67M
weightedAverageShsOutDil 67M 67M 67M 67M 67M 67M 68M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-10-01 2023-07-02 2023-04-02 2023-01-01 2022-10-02
symbol QDEL QDEL QDEL QDEL QDEL QDEL QDEL
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-09 2024-02-29 2023-11-02 2023-08-09 2023-05-04 2023-02-23 2022-11-04
acceptedDate 2024-05-08 18:04:23 2024-02-29 15:29:59 2023-11-01 18:04:39 2023-08-08 18:11:48 2023-05-04 16:09:15 2023-02-23 17:16:50 2022-11-03 20:40:53
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 79M 119M 149M 179M 354M 293M 212M
shortTermInvestments 0 48M 44M 45M 43M 52M 52M
cashAndShortTermInvestments 79M 167M 193M 224M 397M 345M 264M
netReceivables 476M 488M 331M 247M 275M 454M 417M
inventory 583M 578M 552M 542M 529M 524M 536M
otherCurrentAssets 75M 77M 295M 296M 299M 252M 1M
totalCurrentAssets 1 212M 1 311M 1 371M 1 308M 1 499M 1 575M 1 445M
propertyPlantEquipmentNet 1 622M 1 613M 1 542M 1 554M 1 541M 1 520M 1 425M
goodwill 735M 2 492M 2 443M 2 471M 2 491M 2 477M 2 358M
intangibleAssets 2 887M 2 934M 2 977M 3 036M 3 079M 3 124M 3 224M
goodwillAndIntangibleAssets 3 622M 5 426M 5 419M 5 507M 5 570M 5 601M 5 582M
longTermInvestments 500 000 8M 12M 25M 34M 21M 20M
taxAssets 25M 26M 16M 16M 17M 16M 19M
otherNonCurrentAssets 222M 179M 179M 141M 127M 123M 164M
totalNonCurrentAssets 5 491M 7 253M 7 168M 7 242M 7 288M 7 281M 7 210M
otherAssets 0 0 0 0 0 0 0
totalAssets 6 703M 8 563M 8 539M 8 550M 8 787M 8 856M 8 656M
accountPayables 250M 295M 253M 226M 242M 283M 242M
shortTermDebt 190M 167M 193M 207M 208M 208M 208M
taxPayables 10M 11M 2M 2M 16M 52M 67M
deferredRevenue 34M 37M 109M 84M 62M 76M 33M
otherCurrentLiabilities 306M 336M 305M 273M 397M 440M 391M
totalCurrentLiabilities 780M 834M 860M 790M 908M 1 007M 873M
longTermDebt 2 241M 2 274M 2 451M 2 490M 2 563M 2 617M 2 645M
deferredRevenueNonCurrent 14M 14M 14M 0 0 0 0
deferredTaxLiabilitiesNonCurrent 126M 192M 197M 200M 209M 213M 256M
otherNonCurrentLiabilities 235M 243M 52M 69M 111M 84M 2 506M
totalNonCurrentLiabilities 2 616M 2 723M 2 712M 2 758M 2 883M 2 914M 2 988M
otherLiabilities 0 1.000 0 0 0 0 0
capitalLeaseObligations 182M 173M 176M 181M 183M 186M 163M
totalLiabilities 3 396M 3 557M 3 572M 3 548M 3 791M 3 921M 3 860M
preferredStock 0 0 0 0 0 0 0
commonStock 100 000 100 000 100 000 100 000 100 000 0 0
retainedEarnings 482M 2 188M 2 181M 2 194M 2 247M 2 198M 2 168M
accumulatedOtherComprehensiveIncomeLoss -26M -30M -53M -16M -59M -68M -145M
othertotalStockholdersEquity 2 852M 2 848M 2 839M 2 825M 2 809M 2 804M 2 772M
totalStockholdersEquity 3 308M 5 006M 4 967M 5 003M 4 997M 4 935M 4 795M
totalEquity 3 308M 5 006M 4 967M 5 003M 4 997M 4 935M 4 795M
totalLiabilitiesAndStockholdersEquity 6 703M 8 563M 8 539M 8 550M 8 787M 8 856M 8 656M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 6 703M 8 563M 8 539M 8 550M 8 787M 8 856M 8 656M
totalInvestments 500 000 56M 44M 45M 43M 73M 72M
totalDebt 2 613M 2 614M 2 644M 2 697M 2 770M 2 825M 2 852M
netDebt 2 534M 2 495M 2 494M 2 519M 2 417M 2 532M 2 640M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-10-01 2023-07-02 2023-04-02 2023-01-01 2022-10-02
symbol QDEL QDEL QDEL QDEL QDEL QDEL QDEL
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-09 2024-02-29 2023-11-02 2023-08-09 2023-05-04 2023-02-23 2022-11-04
acceptedDate 2024-05-08 18:04:23 2024-02-29 15:29:59 2023-11-01 18:04:39 2023-08-08 18:11:48 2023-05-04 16:09:15 2023-02-23 17:16:50 2022-11-03 20:40:53
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -1 706M 7M -13M -53M 49M 30M 19M
depreciationAndAmortization 115M 115M 113M 115M 114M 117M 104M
deferredIncomeTax -74M -16M -3M -11M 0 89 000 0
stockBasedCompensation 9M 12M 14M -500 000 11M 12M 13M
changeInWorkingCapital -86M -45M -69M -30M 129M 19M -176M
accountsReceivables 26M 36M -90M 27M 187M -31M -51M
inventory -38M -66M -60M -11M -37M -19M -62M
accountsPayables -11M 9M 29M -14M -21M 14M 56M
otherWorkingCapital -64M -25M 53M -33M -129M 55M -119M
otherNonCashItems 1 929M 7M -2M -50M -114M -9M 29M
netCashProvidedByOperatingActivities -700 000 80M 42M -31M 189M 169M -10M
investmentsInPropertyPlantAndEquipment -66M -49M -43M -51M 20M -62M -31M
acquisitionsNet 0 -86M 0 0 0 1 511M 0
purchasesOfInvestments -7M -10M 0 -19M -32M -14M -16M
salesMaturitiesOfInvestments 63M 10M 14M 26M 28M 14M 11M
otherInvestingActivites -10M 79M 8M 3M -86M -1 509M 5M
netCashUsedForInvestingActivites -20M -55M -21M -42M -69M -59M -30M
debtRepayment -13M -54M -52M -72M -52M -52M -52M
commonStockIssued 500 000 4M 800 000 6M 2M 21M 800 000
commonStockRepurchased 0 -7M -500 000 0 0 0 -74M
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites -6M 13M 3M -33M -10M -700 000 -800 000
netCashUsedProvidedByFinancingActivities -19M -58M -49M -100M -60M -32M -126M
effectOfForexChangesOnCash -1M 2M -1M -3M 600 000 2M -2M
netChangeInCash -40M -30M -30M -175M 61M 81M -167M
cashAtEndOfPeriod 79M 119M 150M 180M 355M 294M 213M
cashAtBeginningOfPeriod 119M 149M 180M 355M 294M 213M 381M
operatingCashFlow -700 000 80M 42M -31M 189M 169M -10M
capitalExpenditure -66M -49M -43M -51M -66M -62M -31M
freeCashFlow -67M 32M -2M -82M 189M 108M -40M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-05-08 ET (fiscal 2024 q1)
2023 q4
2024-02-13 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-15 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-05-08 20:05 ET
QuidelOrtho Reports First Quarter 2024 Financial Results
2024-05-02 12:00 ET
QuidelOrtho Appoints Brian J. Blaser as President and Chief Executive Officer
2024-04-17 11:00 ET
QuidelOrtho To Report First Quarter 2024 Financial Results
2024-04-16 13:00 ET
Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain Executives
2024-04-12 22:00 ET
Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Company and Certain Executives
2024-04-10 11:00 ET
QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay
2024-04-02 13:00 ET
QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test
2024-02-26 21:30 ET
QuidelOrtho to Participate in 45th Annual Raymond James Institutional Investor Conference
2024-02-21 12:30 ET
QuidelOrtho Announces Changes in Executive Leadership
2024-02-13 21:05 ET
QuidelOrtho Reports Fourth Quarter and Full-Year 2023 Financial Results
2024-01-23 12:00 ET
QuidelOrtho to Report Fourth Quarter and Full-year 2023 Financial Results
2023-12-22 12:00 ET
QuidelOrtho to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-20 21:05 ET
QuidelOrtho Receives 510(K) Clearance for Savanna® Multiplex Molecular Platform and Savanna® HSV 1+2/VZV PCR Assay
2023-11-16 22:05 ET
QuidelOrtho to Participate in the Evercore ISI Conference
2023-11-01 20:05 ET
QuidelOrtho Reports Third Quarter 2023 Financial Results
2023-10-17 19:43 ET
Powerful Lyme Disease Awareness PSA Featuring Christopher Meloni Illuminates Times Square
2023-10-12 11:00 ET
QuidelOrtho Reports Preliminary Revenue Results for the Third Quarter 2023
2023-09-21 20:05 ET
QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA
2023-08-28 20:05 ET
QuidelOrtho to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-08 20:30 ET
QuidelOrtho Reports Second Quarter 2023 Financial Results
2023-07-25 20:00 ET
QuidelOrtho Ranks No. 1 in Customer Satisfaction for Six Years in a Row
2023-07-24 19:00 ET
QuidelOrtho Partners With BYG4lab® to Strengthen Informatics Offerings
2023-07-18 20:05 ET
QuidelOrtho to Report Second Quarter 2023 Financial Results
2023-05-23 11:00 ET
QuidelOrtho to Participate in William Blair 43rd Annual Growth Stock Conference
2023-05-03 20:05 ET
QuidelOrtho Reports First Quarter 2023 Financial Results
2023-04-13 20:05 ET
QuidelOrtho Reports Preliminary Revenue Results for the First Quarter 2023
2023-03-28 15:05 ET
QuidelOrtho Announces the Formation of the International QuidelOrtho Women’s Leadership Network (QWLN)
2023-03-08 21:05 ET
QuidelOrtho Receives De Novo FDA Authorization for Sofia® 2 SARS Antigen+ FIA
2023-03-02 19:01 ET
QuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor Conference
2023-02-27 16:00 ET
ImageMover and QuidelOrtho Partner to Simplify Test-to-Treat Process for Pharmacies
2023-02-15 21:05 ET
QuidelOrtho Reports Fourth Quarter and Full Year 2022 Financial Results
2023-01-06 21:05 ET
QuidelOrtho Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022
2022-12-28 12:00 ET
QuidelOrtho to Present at the J.P. Morgan Healthcare Conference
2022-12-19 20:15 ET
Health Canada Grants License for Quidel® TriageTrue® High-Sensitivity Troponin I Test to Aid in the Diagnosis of Myocardial Infarction
2022-12-16 16:05 ET
QuidelOrtho and Runda Medical Form Joint Venture to Develop and Manufacture Assays for VITROS® Platform
2022-12-12 21:54 ET
QuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles
2022-11-30 21:05 ET
QuidelOrtho to Host Investor Day on December 13, 2022
2022-11-02 20:05 ET
QuidelOrtho Reports Third Quarter 2022 Financial Results
2022-10-12 20:05 ET
QuidelOrtho Reports Preliminary Revenue Results for Third Quarter 2022
2022-10-04 13:00 ET
Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel Corporation
2022-10-04 13:00 ET
Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel Corporation
2022-09-06 12:00 ET
QuidelOrtho to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
2022-09-01 16:00 ET
Quidel and World Champion Los Angeles Rams Partner to Combat COVID-19 and Promote Health Awareness in the L.A. Community
2022-08-24 13:00 ET
Bacterial Biofilms, Responsible for Up to 75% of All Infectious Diseases in America, Explored in New Webinar From Quidel Corporation
2022-08-17 20:30 ET
QuidelOrtho Announces $300 Million Share Repurchase Authorization
2022-08-04 20:10 ET
QuidelOrtho Reports Second Quarter 2022 Financial Results
2022-07-26 13:35 ET
ORTHO RANKS NO. 1 IN CUSTOMER SATISFACTION FOR 5 YEARS IN A ROW
2022-07-18 20:05 ET
QuidelOrtho to Report Second Quarter 2022 Financial Results on August 4, 2022
2022-06-21 23:00 ET
Quidel Corporation and the American Heart Association join forces to Advance Education and Awareness of Heart Disease in San Diego County
2022-06-09 13:00 ET
Quidel Corp.—Developer of Only FDA-Cleared FIA Rapid Point-of-Care Diagnostic Lyme Disease Test—To Partner With Renowned Global Lyme Alliance to Dramatically Heighten Lyme Disease Awareness
2022-06-09 13:00 ET
QUIDEL CORP.—DEVELOPER OF ONLY FDA-CLEARED FIA RAPID POINT-OF-CARE DIAGNOSTIC LYME DISEASE TEST—TO PARTNER WITH RENOWNED GLOBAL LYME ALLIANCE TO DRAMATICALLY HEIGHTEN LYME DISEASE AWARENESS
2022-05-27 13:00 ET
QuidelOrtho Formed by the Completion of Transaction Combining Quidel and Ortho Clinical Diagnostics
2022-05-26 16:24 ET
Quidel and Ortho Announce Expected Closing of Ortho Transaction
2022-05-26 16:05 ET
Quidel and Ortho Announce Expected Closing of Ortho Transaction
2022-05-16 20:45 ET
Quidel Announces Stockholder Approval of Ortho Acquisition and Business Combination
2022-05-16 20:45 ET
Ortho Clinical Diagnostics Shareholders Approve Quidel Transaction
2022-05-04 20:10 ET
Quidel Reports First Quarter 2022 Financial Results
2022-04-12 22:00 ET
Quidel to Hold Fiscal First Quarter 2022 Financial Results Conference Call on May 4th, 2022
2022-04-07 20:10 ET
Quidel Announces Preliminary Revenue for First Quarter 2022
2022-02-28 23:30 ET
Quidel to Present at Raymond James 43rd Annual Institutional Investors Conference
2022-02-17 21:10 ET
Quidel Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-01 21:10 ET
Quidel to Hold Fiscal Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 17th, 2022
2022-01-06 21:10 ET
Quidel Announces Preliminary Revenue for Fourth Quarter 2021
2022-01-05 14:00 ET
The Signs, Diagnosis and Treatment of Lyme Disease Discussed as Part of New, On-Demand Webinar Hosted by Industry-Leading Quidel Corporation
2022-01-05 14:00 ET
The Signs, Diagnosis and Treatment of Lyme Disease Discussed as Part of New, On-Demand Webinar Hosted by Industry-Leading Quidel Corporation
2022-01-04 22:00 ET
Quidel to Present at 40th Annual J.P. Morgan Healthcare Conference
2021-12-28 23:00 ET
Quidel’s Antigen Tests Detect the Omicron Variant
2021-12-23 12:00 ET
Quidel Corporation Signs Definitive Agreement to Acquire Ortho Clinical Diagnostics
2021-12-15 21:10 ET
Quidel Announces Sponsorship and Community Partnership With the Chicago Blackhawks
2021-12-14 14:00 ET
Series of Infographics From Quidel Corporation Helps Educate Consumers on the Characteristics, Warning Signs and Prevalence of Lyme Disease
2021-12-14 14:00 ET
Series of Infographics From Quidel Corporation Helps Educate Consumers on the Characteristics, Warning Signs and Prevalence of Lyme Disease
2021-11-30 21:10 ET
Quidel Statement on the Omicron Variant
2021-11-19 23:00 ET
Quidel Presents at 33rd Annual Piper Sandler Healthcare Conference
2021-11-04 20:10 ET
Quidel Reports Third Quarter 2021 Financial Results
2021-11-02 16:44 ET
Quidel Corporation to Sponsor Distinguished Speaker Series Conducted by the Bay Area Lyme Foundation
2021-11-02 16:42 ET
Quidel Corporation to Sponsor Distinguished Speaker Series Conducted by the Bay Area Lyme Foundation
2021-10-20 21:30 ET
Quidel to Hold Fiscal Third Quarter 2021 Financial Results Conference Call on November 4th, 2021
2021-10-18 19:11 ET
Pediatric Lyme Disease—‘An Epidemic Within a Pandemic!’—to be Focus of Free Webinar Hosted by Quidel Corporation Oct. 21
2021-10-18 18:56 ET
Pediatric Lyme Disease—'An Epidemic Within a Pandemic!’—to be Focus of Free Webinar Hosted by Quidel Corporation Oct. 21
2021-10-07 20:10 ET
Quidel Announces Preliminary Revenue for Fiscal Third Quarter 2021
2021-09-01 20:10 ET
Quidel to Bring QuickVue® At-Home OTC COVID-19 Tests To CVS Pharmacy
2021-08-10 13:00 ET
LivLyme Foundation Founder Olivia Goodreau to Discuss Perils of Lyme Disease in Free Webinar Hosted by Industry-Leading Quidel Corporation
2021-08-10 13:00 ET
LivLyme Foundation Founder Olivia Goodreau to Discuss Perils of Lyme Disease in Free Webinar Hosted by Industry-Leading Quidel Corporation
2021-08-05 20:10 ET
Quidel Reports Second Quarter 2021 Financial Results
2021-07-26 12:30 ET
Quidel Announces Agreement With Beckman Coulter That Terminates Ongoing Litigation and Transitions BNP Business to Beckman Coulter
2021-07-19 14:30 ET
State of Delaware Selects Quidel for COVID-19 Testing Program at Schools
2021-07-14 20:10 ET
Quidel to Hold Fiscal Second Quarter 2021 Financial Results Conference Call on August 5th, 2021
2021-07-12 13:15 ET
Quidel Receives CE Mark for Savanna® Multiplex Molecular Analyzer and Respiratory Viral Panel
2021-07-12 13:00 ET
New Website Created by Quidel Corporation Provides Consumers With Information and Easy-to-Understand Answers Regarding Lyme Disease
2021-07-12 13:00 ET
New Website Created by Quidel Corporation Provides Consumers With Information and Easy-to-Understand Answers Regarding Lyme Disease
2021-06-29 13:00 ET
Public Service Campaign From Quidel Corporation Directed Toward Heightening Awareness Among Summer Camps of the Dangers of Lyme Disease
2021-06-29 13:00 ET
Public Service Campaign From Quidel Corporation Directed Toward Heightening Awareness Among Summer Camps of the Dangers of Lyme Disease
2021-06-24 17:07 ET
With Lyme Disease on the Rise Nationwide, Quidel Corporation Urges Early Testing With Its Rapid Point-of-Care Test
2021-06-24 17:04 ET
With Lyme Disease on the Rise Nationwide, Quidel Corporation Urges Early Testing With Its Rapid Point-of-Care Test
2021-06-11 20:10 ET
Quidel Receives Amended Emergency Use Authorization for New Sofia® Q Rapid Antigen Test Device
2021-06-10 20:45 ET
Quidel to Present Virtually at Raymond James Human Health Innovation Conference 2021
2021-05-24 21:10 ET
Quidel to Present Virtually at William Blair 41st Annual Growth Stock Conference
2021-05-24 20:10 ET
Health Canada Approves Quidel’s Sofia® SARS Antigen FIA Test for Screening of Asymptomatic Populations With Serial Testing
2021-05-14 20:10 ET
Quidel’s QuickVue® At-Home OTC COVID-19 Test Now Available for Sale Through Amazon
2021-05-06 20:10 ET
Quidel Reports First Quarter 2021 Financial Results
2021-05-06 00:30 ET
Quidel Forms Retail Collaboration With Walgreens for Over-the-Counter Sale of QuickVue® At-Home OTC COVID-19 Tests
2021-05-04 22:00 ET
Quidel to Present Virtually at the BofA Securities 2021 Health Care Conference
2021-04-27 13:00 ET
Teaching Doctors Nationwide How to Recognize and Differentiate Between Lyme Disease, COVID-19 and the Flu in Quidel-Hosted May 5 Webinar
2021-04-27 13:00 ET
Teaching Doctors Nationwide How to Recognize and Differentiate Between Lyme Disease, COVID-19 and the Flu in Quidel-Hosted May 5 Webinar
2021-04-26 23:00 ET
Quidel to Hold Fiscal First Quarter 2021 Financial Results Conference Call on May 6th, 2021
2021-04-22 20:32 ET
Quidel Signs Retail Distribution Agreement to Increase Access to At-Home COVID-19 Testing
2021-04-22 20:30 ET
Quidel Announces Preliminary Revenue for First Quarter 2021
2021-04-13 12:00 ET
Quidel Corporation Partners With the Bay Area Lyme Foundation to Heighten Public Awareness of Lyme Disease
2021-04-13 12:00 ET
Quidel Corporation Partners With the Bay Area Lyme Foundation to Heighten Public Awareness of Lyme Disease
2021-04-06 14:30 ET
Quidel Taps ICS to Collaborate on Next-Gen Multiplex Molecular Diagnostic Instruments for SARS-CoV-2/COVID Pathogen Detection
2021-04-05 12:00 ET
Start of Lyme Disease Season Provides Heightened Risks for Americans Wanting to Go Outdoors After a Year of COVID-19 Restrictions
2021-04-05 12:00 ET
Start of Lyme Disease Season Provides Heightened Risks for Americans Wanting to Go Outdoors After a Year of COVID-19 Restrictions
2021-04-02 00:02 ET
Quidel’s Sofia® SARS Antigen Test Receives Emergency Use Authorization for Screening Use With Serial Testing
2021-04-01 23:30 ET
Quidel Partners With San Diego Padres Organization for COVID-19 Testing
2021-04-01 03:30 ET
Quidel Supports New NIH, CDC Public Health Initiative for At-home COVID-19 Testing
2021-04-01 03:00 ET
Quidel’s QuickVue® At-Home OTC COVID-19 Test Receives Emergency Use Authorization for Screening Use With Serial Testing
2021-03-18 22:00 ET
Quidel Corporation Applauds Biden Administration Plan to Expand COVID-19 Testing
2021-03-01 16:51 ET
Quidel Receives Emergency Use Authorization for QuickVue® At-Home COVID-19 Test
2021-02-22 21:10 ET
Quidel to Present at Upcoming Conferences
2021-02-18 21:10 ET
Quidel Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-03 21:10 ET
Quidel Opens New Manufacturing Facility to Mass Produce QuickVue® Rapid Antigen Tests for COVID-19
2021-01-28 21:10 ET
Quidel to Hold Fiscal Fourth Quarter and Full Year 2020 Financial Results Conference Call on February 18th, 2021
2021-01-07 19:15 ET
Quidel Announces Preliminary Revenue for Fourth Quarter 2020; Will Present Virtually at 39th Annual J.P. Morgan Healthcare Conference
2020-12-23 18:30 ET
Quidel Receives Emergency Use Authorization for Moderately Complex Solana® SARS Molecular Test for COVID-19 Diagnosis
2020-12-21 13:30 ET
Quidel Receives Emergency Use Authorization for QuickVue® SARS Rapid Antigen Test for COVID-19 Diagnosis
2020-12-10 23:00 ET
Quidel Corporation CEO Douglas Bryant Named Executive of the Year in MedTech Dive Awards For 2020
2020-11-19 15:00 ET
Quidel Corporation Hosts Upcoming Webinar to Help Health Professionals Distinguish Lyme Disease, Flu and COVID-19 During Frightening Respiratory Season
2020-11-19 15:00 ET
Quidel Corporation Hosts Upcoming Webinar to Help Health Professionals Distinguish Lyme Disease, Flu and COVID-19 During Frightening Respiratory Season
2020-11-10 23:00 ET
Quidel to Present at Upcoming Conferences
2020-11-10 16:00 ET
Quidel Corporation Triple Winner in International MarCom Awards Competition
2020-11-10 15:00 ET
Quidel Corporation Triple Winner in International MarCom Awards Competition
2020-11-03 21:10 ET
Quidel to Host Virtual Investor Day on November 12, 2020
2020-10-29 20:10 ET
Quidel Reports Third Quarter 2020 Financial Results
2020-10-22 12:00 ET
Quidel Corporation Joins Global Lyme Alliance as Sponsor for the GLA 'Fight Lyme With Avril Lavigne and Friends' Virtual Concert Oct. 24
2020-10-22 12:00 ET
Quidel Corporation Joins Global Lyme Alliance as Sponsor for the GLA ‘Fight Lyme With Avril Lavigne and Friends’ Virtual Concert Oct. 24
2020-10-19 20:10 ET
Quidel to Hold Third Fiscal Quarter 2020 Financial Results Conference Call on October 29th, 2020
2020-10-02 23:15 ET
Quidel Receives Emergency Authorization for First Rapid Antigen “ABC Test”: A Combination Diagnostic Assay for Influenza A+B and COVID-19
2020-10-01 13:00 ET
Quidel Announces Preliminary Revenue for Third Quarter 2020
2020-09-28 22:10 ET
Quidel Corporation Statement on President Trump’s Announcement of Coronavirus Testing Strategy
2020-08-27 18:46 ET
Quidel Provides Business Update at 13th Annual Piper Sandler Med-Tech and Diagnostic California Bus Tour; Another SARS Antigen Entrant Does Not Change Quidel’s Strategy
2020-08-27 18:32 ET
Quidel to Present Today at 13th Annual Piper Sandler Med-Tech and Diagnostics California Bus Tour
2020-08-25 15:00 ET
Webinar Discussing How Lyme Disease Affects Children to Be Held Aug. 27 and Hosted by Quidel Corporation
2020-08-20 18:30 ET
Quidel Concludes Sofia® SARS Antigen Investigation From Vermont
2020-08-20 01:30 ET
Quidel to Update Packaging of Point-of-Care Sofia® SARS Antigen Test for COVID-19 to Include Either Nasal or Nasopharyngeal Swabs
2020-08-12 22:00 ET
Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Health Canada Authorization
2020-08-10 22:38 ET
State of Maryland Allows Point-of-Care Testing for COVID-19; Quidel Expands Training Program
2020-07-31 15:30 ET
Quidel Receives Preliminary Contract Leading to Definitive Agreement for $71 Million Under NIH’s RADx-ATP Program to Accelerate the Expansion of Its Manufacturing Capacity for Sofia® SARS-CoV-2 Antigen Detection Test for Rapid Diagnosis of COVID-19
2020-07-30 20:10 ET
Quidel Reports Second Quarter 2020 Financial Results
2020-07-29 20:10 ET
CORRECTING and REPLACING Quidel to Present Virtually at the Canaccord Genuity 40th Annual Growth Conference
2020-07-22 15:00 ET
Published National Findings in Lyme Disease Testing to Be Discussed on July 30 Webinar Hosted by Quidel Corporation
2020-07-18 03:00 ET
Quidel’s Sofia® SARS Antigen FIA Updates EUA Performance Data to 96.7% PPA Versus PCR; Product Supports U.S. Initiatives to Expand Access to COVID-19 Testing in Nursing Homes; Receives CE Mark for Use With Sofia® and Sofia® 2 Instruments
2020-07-13 22:10 ET
Quidel to Hold Second Fiscal Quarter 2020 Financial Results Conference Call on July 30th, 2020
2020-07-06 21:00 ET
Quidel Announces Preliminary Revenue for Second Quarter 2020
2020-06-11 22:49 ET
Quidel Receives BARDA Funding to Develop Point-of-Care Diagnostic Assay That Includes COVID-19
2020-06-11 15:30 ET
Quidel Announces Jack Schuler Will Retire From Quidel’s Board of Directors
2020-06-09 23:00 ET
Quidel Receives Amended Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay Using Sofia 1 Instrument
2020-05-26 20:10 ET
Quidel to Present Virtually at William Blair 40th Annual Growth Stock Conference
2020-05-19 00:30 ET
Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Emergency Use Authorization and CE Mark for Molecular Detection of COVID-19, Without Extraction Step
2020-05-09 01:00 ET
Quidel Receives Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay
2020-05-06 20:10 ET
Quidel Reports First Quarter 2020 Financial Results
2020-04-29 21:00 ET
Quidel to Present Virtually at the BofA Securities 2020 Health Care Conference
2020-04-22 21:00 ET
Quidel’s Lyra® Direct SARS-CoV-2 Assay Submitted for Emergency Use Authorization for Molecular Detection of COVID-19, Without Extraction Step
2020-04-21 20:10 ET
Quidel to Hold First Quarter 2020 Financial Results Conference Call on May 6th, 2020
2020-03-26 00:45 ET
Quidel’s Lyra® SARS-CoV-2 Assay Receives Authorization for Expanded Use for Molecular Detection of COVID-19; Also Receives CE Mark, Health Canada Authorization
2020-03-18 00:30 ET
Quidel Receives Emergency Use Authorization for Molecular COVID-19 Diagnostic Assay
2020-02-18 21:10 ET
Quidel to Present at Upcoming Conferences
2020-02-12 21:10 ET
Quidel Reports Fourth Quarter and Full Year 2019 Financial Results
2020-01-28 21:10 ET
Quidel to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on February 12th, 2020
2020-01-09 23:00 ET
Quidel Announces Preliminary Revenue for Fourth Quarter 2019
2019-11-14 23:00 ET
Quidel to Present at Upcoming Conferences
2019-10-30 20:10 ET
Quidel Reports Third Quarter 2019 Financial Results
2019-10-17 22:00 ET
Quidel to Hold Third Quarter 2019 Financial Results Conference Call on October 30th, 2019

SEC forms

Show financial reports only

SEC form 10
2024-05-09 00:00 ET
Quidel published news for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Quidel published news for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Quidel reported for 2024 q1
SEC form 10
2024-02-29 00:00 ET
Quidel reported for 2023 q4
SEC form 8
2024-02-13 00:00 ET
Quidel published news for 2023 q4
SEC form 8
2024-02-13 00:00 ET
Quidel published news for 2023 q4
SEC form 10
2023-11-02 00:00 ET
Quidel published news for 2023 q3
SEC form 10
2023-11-01 18:04 ET
Quidel published news for 2023 q3
SEC form 8
2023-11-01 16:12 ET
Quidel reported for 2023 q3
SEC form 8
2023-10-12 00:00 ET
Quidel published news for 2023 q3
SEC form 10
2023-08-09 00:00 ET
Quidel published news for 2023 q2
SEC form 10
2023-08-08 18:11 ET
Quidel published news for 2023 q2
SEC form 6
2023-08-08 17:00 ET
Quidel reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Quidel published news for 2023 q2
SEC form 10
2023-05-04 00:00 ET
Quidel published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
Quidel published news for 2023 q1
SEC form 6
2023-04-13 16:22 ET
Quidel published news for 2023 q1
SEC form 8
2023-04-13 00:00 ET
Quidel published news for 2023 q1
SEC form 6
2023-04-10 16:33 ET
Quidel published news for 2023 q1
SEC form 10
2023-02-23 17:16 ET
Quidel reported for 2022 q4
SEC form 10
2023-02-23 00:00 ET
Quidel reported for 2022 q4
SEC form 6
2023-02-15 16:16 ET
Quidel published news for 2022 q4
SEC form 8
2023-02-15 00:00 ET
Quidel reported for 2022 q4
SEC form 6
2023-01-06 16:26 ET
Quidel published news for 2022 q4
SEC form 8
2023-01-06 00:00 ET
Quidel published news for 2022 q4
SEC form 6
2022-12-13 17:22 ET
Quidel published news for 2022 q3
SEC form 6
2022-12-05 07:48 ET
Quidel published news for 2022 q3
SEC form 10
2022-11-04 00:00 ET
Quidel reported for 2022 q3
SEC form 10
2022-11-03 20:40 ET
Quidel reported for 2022 q3
SEC form 6
2022-11-02 16:11 ET
Quidel published news for 2022 q3
SEC form 8
2022-11-02 00:00 ET
Quidel reported for 2022 q3
SEC form 6
2022-10-12 16:11 ET
Quidel published news for 2022 q3
SEC form 8
2022-10-12 00:00 ET
Quidel published news for 2022 q3
SEC form 6
2022-08-17 16:55 ET
Quidel published news for 2022 q2
SEC form 6
2022-08-10 17:27 ET
Quidel published news for 2022 q2
SEC form 10
2022-08-05 17:27 ET
Quidel reported for 2022 q2
SEC form 10
2022-08-05 00:00 ET
Quidel reported for 2022 q2
SEC form 6
2022-08-04 16:34 ET
Quidel published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Quidel reported for 2022 q2
SEC form 6
2022-07-07 17:02 ET
Quidel published news for 2022 q2
SEC form 6
2022-06-06 16:43 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:13 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:12 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:07 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:06 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:05 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:03 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:02 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:02 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:01 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 17:01 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 16:59 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 16:59 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 16:57 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 16:45 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 16:44 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 16:42 ET
Quidel published news for 2022 q1
SEC form 6
2022-06-01 16:41 ET
Quidel published news for 2022 q1
SEC form 6
2022-05-27 09:10 ET
Quidel published news for 2022 q1